Gubra A/S
ISIN: DK0062266474 | Ticker: GUBRA | LEI: 254900T17RRFZONO6W53
Country: Denmark
Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of development milestone payments and potential royalties from the D&P business.
Year founded2008
Served areaWorldwide
Headcount200
HeadquartersHørsholm Kongevej 11B, 2970 Hørsholm – Denmark
| Line item in (dkk) | 01.01.2022 | 01.07.2022 | 01.01.2023 | 01.07.2023 |
|---|---|---|---|---|
| Assets | N/A | N/A | 262,902,000.00 | 623,417,000.00 |
| Noncurrent Assets | N/A | N/A | 70,888,000.00 | 83,754,000.00 |
| Land And Buildings | N/A | N/A | 12,635,000.00 | 9,176,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 7,330,000.00 | 10,084,000.00 |
| Deferred Tax Assets | N/A | N/A | 3,759,000.00 | 7,113,000.00 |
| Longterm Deposits | N/A | N/A | 4,063,000.00 | 4,089,000.00 |
| Current Assets | N/A | N/A | 192,014,000.00 | 539,663,000.00 |
| Current Trade Receivables | N/A | N/A | 36,093,000.00 | 24,389,000.00 |
| Current Prepayments | N/A | N/A | 9,941,000.00 | 3,937,000.00 |
| Other Current Receivables | N/A | N/A | 5,136,000.00 | 7,223,000.00 |
| Other Current Financial Assets | N/A | N/A | 65,664,000.00 | 420,611,000.00 |
| Cash and cash equivalents | 115,785,000.00 | 90,479,000.00 | 71,925,000.00 | 83,503,000.00 |
| Equity And Liabilities | N/A | N/A | 262,902,000.00 | 623,417,000.00 |
| Equity | 151,463,000.00 | 86,479,000.00 | 108,207,000.00 | 506,428,000.00 |
| Issued Capital | N/A | N/A | 133,000.00 | 16,350,000.00 |
| Retained Earnings | N/A | N/A | 108,074,000.00 | 490,078,000.00 |
| Liabilities | N/A | N/A | 154,695,000.00 | 116,989,000.00 |
| Noncurrent Liabilities | N/A | N/A | 60,962,000.00 | 67,412,000.00 |
| Other Noncurrent Liabilities | N/A | N/A | 0.00 | 848,000.00 |
| Current Liabilities | N/A | N/A | 93,733,000.00 | 49,576,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | N/A | 10,592,000.00 | 6,768,000.00 |
| Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 3,171,000.00 | 3,444,000.00 |
| Current Contract Liabilities | N/A | N/A | 31,851,000.00 | 17,926,000.00 |
| Current Tax Liabilities Current | N/A | N/A | 4,437,000.00 | 2,216,000.00 |
| Other Current Liabilities | N/A | N/A | 16,198,000.00 | 11,488,000.00 |
| Line item in (dkk) | 01.01.2022/ 01.07.2022 |
01.01.2023/ 01.07.2023 |
|---|---|---|
| Revenue | 97,683,000.00 | 101,817,000.00 |
| Other Income | 975,000.00 | 1,086,000.00 |
| Profit Loss From Operating Activities | -9,021,000.00 | -22,810,000.00 |
| Finance Income | 12,000.00 | 2,540,000.00 |
| Finance Costs | 938,000.00 | 2,871,000.00 |
| Profit Loss Before Tax | -9,946,000.00 | -23,142,000.00 |
| Income Tax Expense Continuing Operations | -3,092,000.00 | -5,003,000.00 |
| Profit (loss) | -6,854,000.00 | -18,139,000.00 |
| Line item in (dkk) | 01.01.2022 | 01.07.2022 | 01.01.2023 | 01.07.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -6,854,000.00 | N/A | -18,139,000.00 |
| Other Adjustments For Noncash Items | N/A | 21,846,000.00 | N/A | 5,750,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 986,000.00 | N/A | 299,000.00 |
| Interest Received Classified As Operating Activities | N/A | 12,000.00 | N/A | 1,140,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 912,000.00 | N/A | 2,221,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 55,494,000.00 | N/A | -13,645,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 | N/A | 5,000,000.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 0.00 | N/A | 419,335,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | N/A | 65,664,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 5,504,000.00 | N/A | 1,111,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -7,409,000.00 | N/A | -362,528,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | N/A | 500,000,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 4,539,000.00 | N/A | 124,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 1,078,000.00 | N/A | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,761,000.00 | N/A | 3,451,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 66,013,000.00 | N/A | 68,310,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -73,391,000.00 | N/A | 387,721,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -25,306,000.00 | N/A | 11,547,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | N/A | 31,000.00 |
| Cash and cash equivalents | 115,785,000.00 | 90,479,000.00 | 71,925,000.00 | 83,503,000.00 |
Please note that some sums might not add up.
DK0062266474
LEI254900T17RRFZONO6W53
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.